GLP-1
JP Morgan Targets Weight Loss Drugs With $500M Fund
JP Morgan Private Capital has raised over $500 million for a life sciences fund targeting private biotech companies and the booming weight-loss drug space.
Squared Circles Gets $40M To Launch New Health & Wellness Brands
Backed by L Catterton, Squared Circles is eyeing projects including nutritious food products for GLP-1 users and whole-body health for men.
Hims & Hers, Nestle Enter the GLP-1 Race
Hims & Hers will now provide access to compounded GLP-1s for eligible consumers at a discounted rate compared to brand-name prescriptions.
Dr. Rachel Goldman on the Complex World of Weight Loss Drugs
A Ro advisor, Dr. Rachel speaks about the confluence of mental and physical health in weight loss and misconceptions around GLP-1s.
The New Normal? Fitness Brands Increasingly Embrace Weight Loss Meds
As consumers flock to GLP-1s, major fitness industry players like Life Time and Xponential are eager to get in on the weight-loss drug craze.
Low-Cost Gyms Poised To Thrive Amid Rise of Weight Loss Drugs
The rise of GLP-1s will cause more people to seek gym memberships and could benefit the fitness industry in other ways, analysts predict.
The Rise of Weight-Loss Medications: Are Diet Companies Doomed?
While body positivity was popular in recent years, the pendulum seems to have swung the other way with the rise of weight-loss medications.
